New Haven, CTNCT05726032Now EnrollingIRB Ready

Cirrhosis Clinical Trial in New Haven, CT

Access cutting-edge cirrhosis treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Yale University

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access cirrhosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related cirrhosis treatment provided free

Apply for This New Haven Location

Check if you qualify for this cirrhosis clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Cirrhosis Study in New Haven

A proof-of-concept placebo-controlled trial to explore the acute and 14-day effects of empagliflozin on natriuresis and total body water in patients with cirrhosis and ascites. We will additionally investigate its effect on neurohumoral activation, and renal hemodynamics.

Sponsor: Yale University

Who Can Participate

Inclusion Criteria

Patients with cirrhosis and ascites on a stable dose of diuretics (spironolactone +/- loop-diuretics based on AASLD guidelines)10 and who do not require large volume paracenteses
eGFR \>= 30mL/min/1.73 m2
\>=18 years old

Exclusion Criteria

Hospitalization due to a complication of cirrhosis in the previous 8 weeks (e.g. variceal hemorrhage, encephalopathy, acute kidney injury, spontaneous bacterial peritonitis)
Direct bilirubin \>=3 mg/dL
Systolic blood pressure \< 100 mmHg
Active malignancy including hepatocellular carcinoma undergoing treatment
History of bladder dysfunction, incontinence, pyelonephritis, urosepsis, or frequent urinary tract infections
Use of SGLT-2 inhibitors in the last 10 days, or previous use with intolerance
Type 1 diabetes
History of frequent hypoglycemic episodes
Use of a non-loop diuretic aside from aldosterone antagonists or amiloride as they are not standard of care in patients with cirrhosis and could potentially increase the risk of hypovolemia when combined with the standard treatment for ascites along with SGLT2 inhibitor.
Hepatic hydrothorax requiring thoracentesis in the prior 8 weeks
Hepatic encephalopathy grade II or greater at the time of enrollment
Patients who have had TIPS placed
Previous liver transplant
Participation in another trial with an investigational drug within the 30 days prior to informed consent
Pregnancy or breastfeeding
Inability to give written informed consent or follow study protocol (e.g. clinically-significant psychiatric, addictive, or neurological disease)
Change in diuretic dose in the prior 2 weeks
Patients with hospitalization for alcoholic hepatitis in the past 6 months
Significant worsening of creatinine (more than 50% increase) in the past 4 weeks
MELD-Na \> or equal to 20
Hemoglobin \<8

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT05726032) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Cirrhosis Treatment Options in New Haven, CT

If you're searching for cirrhosis treatment options in New Haven, CT, this clinical trial (NCT05726032) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cirrhosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all cirrhosis clinical trials near you to find additional studies recruiting in your area.

More Primary Biliary Cholangitis Trials in New Haven, CT

See all primary biliary cholangitis clinical trials recruiting in New Haven — not just this study.

Browse Primary Biliary Cholangitis Trials in New Haven →

Browse More Trials by Condition

Primary Biliary Cholangitis TrialsLiver Disease TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT